So that's how it works, says Resverlogix of its lead product
This article was originally published in Scrip
Executive Summary
The Canadian biotech company Resverlogix has discovered exactly how its lead cardiovascular product, RVX-208, increases the production of apolipoprotein, in a finding that it says has implications for its entire pipeline.